Health1 min read

Massive hope for pancreatic cancer pill after trial saw tumours vanish

By · Published by Everything Blog

In short

In an early trial of 61 patients with spreading cancer, the KRAS inhibitor daraxonrasib combined with chemotherapy halted tumour progression in 90% of participants. The combined regimen appeared to nearly double the duration of disease control, causing tumours to shrink or disappear in over 60% of cases. Scans showed no detectable disease in roughly one in 12 patients, offering an encouraging development for the common cancer with the lowest UK survival rate. However, doctors caution that the treatment is not a definitive cure because the disease can eventually return.

Key points

  • The medication functions by targeting and shutting off specific KRAS mutations that drive…: The medication functions by targeting and shutting off specific KRAS mutations that drive tumour growth in pancreatic, lung, and ovarian cancers.
  • Although the drug has secured approval in the United States, doctors emphasize that the t…: Although the drug has secured approval in the United States, doctors emphasize that the therapy remains a management tool rather than a cure.
  • Medical experts require longer clinical studies to establish whether the therapy can deli…: Medical experts require longer clinical studies to establish whether the therapy can deliver lasting remission beyond the initial year-and-a-half monitoring period.

Sources checked by our analysis pipeline: 1

- Published

Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades - a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers.

Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in early medical trials.

Tumours stopped growing in almost all of the 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

But doctors stress it is a long way from knowing how long it might keep the disease at bay and should not be seen as a cure.

Incredibly exciting

Cancer Research UK called it "the biggest leap forward in decades" for pancreatic cancer patients.

The charity's Dr Sam Godfrey told BBC News that the results were incredibly exciting. "What this new drug has done is it's found a way of drugging the undruggable.

"We are finally seeing progress in pancreatic cancer which is so long overdue."

Pancreatic cancer is notoriously hard to…

Health